SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Erasca, Tango Therapeutics Launch Phase 1/2 Cancer Drug Trial

Valid market news retained in the public archive without immediate LiveCast distribution.

ERASTNGX

Story updates

01:38:31 PM UTC
SquawkNews
Tango Therapeutics and Erasca opened enrollment in a Phase 1/2 study of vopimetostat with ERAS-0015 for MTAP-deleted pancreatic cancer and MTAP-deleted/RAS-mutant NSCLC. The trial will assess dose, safety and antitumor activity.Material DetailsContext by AI AnalystThis is an early-stage clinical de…

Related stories